pharmaceutical-investing Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma
pharmaceutical-investing Reata Pharmaceuticals Announces First Quarter 2018 Financial Results and an Update on Development Programs
pharmaceutical-investing OncoMed Announces First Quarter 2018 Financial Results and Operational Highlights
pharmaceutical-investing miRagen Therapeutics Announces New Interim Data From Phase 1 Clinical Trial of Cobomarsen in Mycosis Fungoides
pharmaceutical-investing Xenon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
pharmaceutical-investing Nabriva Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
pharmaceutical-investing Cellular Biomedicine Group Reports First Quarter 2018 Financial Results and Highlights Operational Progress
pharmaceutical-investing Verona Pharma plc Operational Update and Financial Results for the First Quarter Ended March 31, 2018
Eloxx Pharmaceuticals Announces FDA Grant of Orphan-Drug Designation for Investigational Drug ELX-02 for Treatment of Cystinosis
pharmaceutical-investing Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006
Rio Silver Launches Metallurgical Program to De-Risk Processing and Optimize Silver Recoveries at Maria Norte
